FLT3LG and neoplasm: Rather than the injection of exogenously expanded and activated cDCs (DC vaccination; described below), it has been shown in pre-clinical studies that systemic injection of Flt3L leads to systemic expansion of the cDC1 population, increasing the number of these cells within B16 melanomas and significantly delaying tumor growth (10).